One of the more common myths about hormone therapy (ADT) to treat prostate cancer is that its effectiveness will last only for one and a half to two years. For some men this might be true, but it is not a reality in today’s prostate cancer landscape. What makes this myth worse is that it [...]
A subgroup analysis of the phase III trials of Provenge (Sipuleucel-T) suggests that there might be a dramatic role for Provenge in African-American men who have advanced prostate cancer that has become castration-resistant (mCRPC). The analysis, which was released at the American Urological Association 2012 Annual Scientific Meeting, was headed up by Colonel David G. [...]
Cancer related fatigue (CRF) is a common problem suffered by many cancer survivors, including men with advanced prostate cancer. Whether the fatigue is a result of the cancer or of the treatment doesn’t really matter. What matters is that you are fatigued and unable to live your life as you wish. CRF can affect us [...]
Androgen deprivation therapy (ADT) is an old standby for the treatment of men with metastatic or advanced prostate cancer. We have long known that testosterone plays an integral role in the progression of prostate cancer, thus we often use it as an initial treatment for men who become metastatic. ADT is used both for men [...]
The National Health Service cost regulators for England and Wales have recommended the use of Zytiga in the treatment of men with castrate resistant advanced prostate cancer. The National Institute for Health and Clinical Excellence (NICE) has published a final guidance endorsing Zytiga as an NHS treatment option for men with advanced, metastatic, castration resistant [...]
Many of us in the United States with advanced prostate cancer who have failed Zytiga are looking to enter the Early Access MDV-3100 Clinical Trial. However, you need to be aware that there are some requirements you will need to meet prior to starting MDV-3100. You will need to wait 30 days after stopping Zytiga [...]
Recently, it was announced that there was a submission by Astellas and Medivation to the European Regulatory Agency for Enzalutamide (MDV-3100) for the treatment of men with advanced prostate cancer post-chemotherapy The basis of the submission was the pivotal phase 3 AFFIRM study. The Marketing Authorization Application (MAA) that was made to the European Medicines [...]
There has been an on-going debate on the advanced prostate cancer on-line support group about the issue of the efficacy of Provenge in light of the expectation of a person's increasing PSA number while getting the treatment. For many men with advanced prostate cancer this is a reason they elect to pass on this treatment [...]
I have heard some occasional discussion that once (that is if) enzalutamide (MDV-3100) is approved by the FDA for the treatment of men with advanced prostate cancer, it will over shadow Provenge. On the contrary, I believe that the approval of enzalutamide will actually encourage additional use of Provenge resulting in the increasing use of [...]
Advanced registered nurse practitioners (ARNP) had been integrated into the oncology team at the Mayo Clinic in Jacksonville, Florida with the purpose of discussing palliative care intervention for persons newly diagnosed with metastatic cancer. The team found that this type of intervention improved emotional and mental quality of life (QoL) for those patients who participated [...]
